SCHEMBL1086552

SCHEMBL1086552

O=C(NCc1ccc(Cl)c(Cl)c1)N1CCC2(CC1)CN(Cc1ccc3ccccc3c1)C(=O)O2

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.46
TPSAB1 Q15661 1/20 0.45
ERN1 O75460 1/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
RECQL P46063 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CHRNA7 P36544 5/20 0.42
EPHX2 P34913 1/20 0.41
FAAH O00519 2/20 0.41
HDAC1 Q13547 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
CCR3 P51677 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1086318 0.87 ERN1 (0.54) HRH3ERN1KMT2AMEN1LMNA
SCHEMBL4259750 0.87 TSHR (0.40) KMT2AMEN1SMN1; SMN2TRPV1CCR3
SCHEMBL1085987 0.87 HRH3 (0.45) HRH3ERN1KMT2AMEN1LMNA
SCHEMBL1086470 0.81 FAAH (0.42) KMT2AMEN1FAAHHDAC1
SCHEMBL1086756 0.81 CCR3 (0.42) HDAC1CCR3
SCHEMBL4486191 0.80 MMP13 (0.40) KMT2AFAAHHDAC1PKM
SCHEMBL4486194 0.78 TACR2 (0.41) KMT2AFAAHHDAC1PKM
SCHEMBL1086533 0.77 FAAH (0.55) KMT2AMEN1SMN1; SMN2FAAH
SCHEMBL1086445 0.77 P2RX7 (0.40)
SCHEMBL4259054 0.76 MEN1 (0.42) KMT2AMEN1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US claimed
EP-1910381-B1 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2009-06-03 EP claimed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US claimed
US-8153795-B2 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs GRUENENTHAL GMBH (DE) 2012-04-10 US disclosed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs DDO, DAO, OTC HRH3 2574/4885TPSAB1 2249/4885ERN1 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.